<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962191</url>
  </required_header>
  <id_info>
    <org_study_id>R20-00012</org_study_id>
    <nct_id>NCT04962191</nct_id>
  </id_info>
  <brief_title>Idylla EGFR Lung Trial</brief_title>
  <official_title>Technology Study: Measuring Potential Impact of Research Use Only Rapid EGFR Testing on Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthony Magliocco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protean BioDiagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective, observational study will compare the results of a BioCartis' EGFR&#xD;
      mutation test on the Idylla platform with test results from SoC pathology results from tissue&#xD;
      biopsies in the same setting. A comparable rapid testing platform for EGFR may serve as a&#xD;
      more accessible means to diagnose, and overall, more patients treated successfully with&#xD;
      targeted therapies. Up to 150 samples will be tested and compared with existing results.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the results of a BioCartis' EGFR mutation test on theIdylla platform&#xD;
      with test results from standard of care (SoC) pathology results from tissue biopsies. The&#xD;
      Idylla™ EGFR Mutation Test, performed on the BioCartis Idylla™ System, is an in vitro&#xD;
      diagnostic test for the qualitative detection of exon 18, exon 20, and exon 21 mutations.&#xD;
      Additionally, exon 19 deletions and exon 20 insertions in the EGFR oncogene. A rapid testing&#xD;
      platform for EGFR may serve as a more accessible means to diagnose, and overall, more&#xD;
      patients treated successfully with targeted therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Idylla EGFR Mutation Test</measure>
    <time_frame>Retrospective tissue samples no longer than 5 years old</time_frame>
    <description>The primary outcome measured is if the Idylla EGFR Mutation Test is a possible alternative to diagnose EGFR mutation status in tissue samples.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Technology</condition>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>Lung Cancer</arm_group_label>
    <description>The Idylla EGFR Mutation Test, performed on the BioCartis Idylla System, is an in vitro diagnostic test for the qualitative detection of exon mutations. One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. This study can help test the BioCartis Idylla System against standard of care (SoC) pathology results from tissue biopsies in the same setting, ultimately being able to diagnose with a fraction of the tissue previously needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Idylla EGFR Mutation Test</intervention_name>
    <description>This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.</description>
    <arm_group_label>Lung Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Target population is patients diagnosed with primary lung cancer and potentially have known&#xD;
        EGFR mutation status.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with primary lung cancer&#xD;
&#xD;
          -  Data from primary diagnosis must be included in pathology report or data entry.&#xD;
&#xD;
          -  Detailed pathology report included for all samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Limited or no tissue available&#xD;
&#xD;
          -  Only tissue available is from fine needle aspiration&#xD;
&#xD;
          -  Tissue blocks older than 5 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Magliocco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEO and Founder</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah Park, BS</last_name>
    <phone>754-242-9682</phone>
    <email>hannah.park@proteanbiodx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>So Hyeon Park, MS</last_name>
    <phone>754-242-9682</phone>
    <email>sohyeon.park@proteanbiodx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>6555 Sanger Rd, Suite 260</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Park, BS</last_name>
      <phone>754-242-9682</phone>
      <email>hannah.park@proteanbiodx.com</email>
    </contact>
    <contact_backup>
      <last_name>So Hyeon Park, MS</last_name>
      <phone>754-242-9682</phone>
      <email>sohyeon.park@proteanbiodx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Magliocco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.proteanbiodx.com/</url>
    <description>Company Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Protean BioDiagnostics</investigator_affiliation>
    <investigator_full_name>Anthony Magliocco</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Protean BioDiagnostics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

